Mark E. Gurney

16.0k total citations · 3 hit papers
89 papers, 11.0k citations indexed

About

Mark E. Gurney is a scholar working on Neurology, Genetics and Molecular Biology. According to data from OpenAlex, Mark E. Gurney has authored 89 papers receiving a total of 11.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Neurology, 18 papers in Genetics and 17 papers in Molecular Biology. Recurrent topics in Mark E. Gurney's work include Amyotrophic Lateral Sclerosis Research (29 papers), Neurological diseases and metabolism (13 papers) and Neurogenetic and Muscular Disorders Research (13 papers). Mark E. Gurney is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (29 papers), Neurological diseases and metabolism (13 papers) and Neurogenetic and Muscular Disorders Research (13 papers). Mark E. Gurney collaborates with scholars based in United States, Ireland and Iceland. Mark E. Gurney's co-authors include Mauro C. Dal Canto, Young W. Kwon, Ping Zhai, M. C. Dal Canto, Arlene Y. Chiu, Teepu Siddique, Robert Sufit, Haifeng Pu, Han‐Xiang Deng and Afif Hentati and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Mark E. Gurney

88 papers receiving 10.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation

1994 3.4k citations Mark E. Gurney, Mauro C. Dal Canto et al. Science profile →
Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity

1999 1.2k citations Riqiang Yan, Michael J. Bienkowski et al. Nature profile →
aph-1 and pen-2 Are Required for Notch Pathway Signaling, γ-Secretase Cleavage of βAPP, and Presenilin Protein Accumulation

2002 655 citations Jinhe Li, Mark E. Gurney et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark E. Gurney United States	36	5.9k	3.9k	3.2k	2.7k	1.8k	89	11.0k
Wim Robberecht Belgium	58	8.3k 1.4×	3.9k 1.0×	4.4k 1.4×	1.9k 0.7×	2.2k 1.2×	133	11.4k
Mari Yoshida Japan	50	7.0k 1.2×	4.8k 1.2×	1.9k 0.6×	3.4k 1.3×	2.2k 1.2×	311	11.5k
Robert Bowser United States	50	3.3k 0.5×	4.0k 1.0×	1.5k 0.5×	1.7k 0.6×	1.2k 0.6×	153	7.8k
Jennifer Bruce United States	27	4.2k 0.7×	2.8k 0.7×	1.7k 0.6×	1.9k 0.7×	892 0.5×	45	7.3k
Linda K. Kwong United States	41	10.1k 1.7×	6.0k 1.5×	4.1k 1.3×	4.6k 1.7×	1.6k 0.9×	87	14.4k
Han‐Xiang Deng United States	38	5.5k 0.9×	3.0k 0.8×	3.0k 0.9×	1.0k 0.4×	1.4k 0.8×	107	8.2k
Jean‐Philippe Loeffler France	52	3.2k 0.5×	3.2k 0.8×	1.9k 0.6×	1.1k 0.4×	1.8k 1.0×	134	7.7k
Christine Vande Velde Canada	32	4.1k 0.7×	3.7k 1.0×	2.3k 0.7×	949 0.4×	925 0.5×	58	7.1k
Zuoshang Xu United States	46	3.6k 0.6×	5.2k 1.3×	1.9k 0.6×	1.1k 0.4×	1.4k 0.7×	86	9.3k
Paul R. Heath United Kingdom	48	2.5k 0.4×	3.3k 0.9×	1.4k 0.4×	1.3k 0.5×	972 0.5×	131	6.7k

Countries citing papers authored by Mark E. Gurney

Since Specialization

Citations

This map shows the geographic impact of Mark E. Gurney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Gurney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Gurney more than expected).

Fields of papers citing papers by Mark E. Gurney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Gurney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Gurney. The network helps show where Mark E. Gurney may publish in the future.

Co-authorship network of co-authors of Mark E. Gurney

This figure shows the co-authorship network connecting the top 25 collaborators of Mark E. Gurney. A scholar is included among the top collaborators of Mark E. Gurney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark E. Gurney. Mark E. Gurney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Csizmar, Clifford M., Mark E. Gurney, Rashmi Kanagal‐Shamanna, et al.. (2024). Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML). Blood. 144(Supplement 1). 1820–1820. 1 indexed citations

Tefferi, Ayalew, Clifford M. Csizmar, Mark E. Gurney, et al.. (2024). PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis. American Journal of Hematology. 99(12). 2321–2327. 2 indexed citations

Prakash, Ajay, Mark E. Gurney, Hannah Prendeville, et al.. (2024). NK cell line modified to express a potent, DR5 specific variant of TRAIL, show enhanced cytotoxicity in ovarian cancer models. Heliyon. 10(15). e34976–e34976. 2 indexed citations

Baranwal, Anmol, Mark E. Gurney, Aref Al‐Kali, et al.. (2024). The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance. Blood Advances. 8(12). 3130–3139. 5 indexed citations

Gurney, Mark E., Anmol Baranwal, Patricia T. Greipp, et al.. (2023). The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms. British Journal of Haematology. 202(2). 279–283. 4 indexed citations

Gurney, Mark E., Sarah Corcoran, Sarah Brophy, et al.. (2022). Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor–natural killer cells. Cytotherapy. 24(11). 1087–1094. 22 indexed citations

Fabre, J & Mark E. Gurney. (2009). Limitations of current therapies to prevent thrombosis: a need for novel strategies. Molecular BioSystems. 6(2). 305–315. 28 indexed citations

Singh, Jasbir, Wayne E. Zeller, Nian Zhou, et al.. (2009). Structure−Activity Relationship Studies Leading to the Identification of (2E)-3-[l-[(2,4-Dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a Potent and Selective Prostanoid EP3 Receptor Antagonist, as a Novel Antiplatelet Agent That Does Not Prolong Bleeding. Journal of Medicinal Chemistry. 53(1). 18–36. 34 indexed citations

Ellerbrock, Brenda R., et al.. (2004). Screening for Presenilin Inhibitors Using the Free-Living Nematode, Caenorhabditis elegans. SLAS DISCOVERY. 9(2). 147–152. 27 indexed citations

10.

Li, Jinhe, Adele M. Pauley, John R. Brashler, et al.. (2002). SEL‐10 interacts with presenilin 1, facilitates its ubiquitination, and alters A‐beta peptide production. Journal of Neurochemistry. 82(6). 1540–1548. 58 indexed citations

11.

Poljak, Anne, Roger Pamphlett, Mark E. Gurney, & Mark W. Duncan. (2000). Measurement ofo- andm-tyrosine as markers of oxidative damage in motor neuron disease. Redox Report. 5(2-3). 137–140. 2 indexed citations

12.

Yan, Riqiang, Michael J. Bienkowski, Mary E. Shuck, et al.. (1999). Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity. Nature. 402(6761). 533–537. 1176 indexed citations breakdown →

13.

Cho, Kyu-Jung, Yoon Hee Chung, Chung Min Shin, et al.. (1999). Reactive astrocytes express p53 in the spinal cord of transgenic mice expressing a human Cu/Zn SOD mutation. Neuroreport. 10(18). 3939–3943. 23 indexed citations

14.

Hall, Edward D., Paula K. Andrus, Jo A. Oostveen, Timothy J. Fleck, & Mark E. Gurney. (1998). Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS. Journal of Neuroscience Research. 53(1). 66–77. 149 indexed citations

15.

Shibata, Noriyuki, Makio Kobayashi, Mauro C. Dal Canto, et al.. (1998). Presence of Cu/Zn superoxide dismutase (SOD) immunoreactivity in neuronal hyaline inclusions in spinal cords from mice carrying a transgene for Gly93Ala mutant human Cu/Zn SOD. Acta Neuropathologica. 95(2). 136–142. 38 indexed citations

16.

Gurney, Mark E.. (1995). Correction. Science. 269(5221). 149–149. 1 indexed citations

17.

Okada, Takeshi, et al.. (1994). HIV Type 1 Infection of CD4 ⁺ T Cells Depends Critically on Basic Amino Acid Residues in the V3 Domain of Envelope Glycoprotein 120. AIDS Research and Human Retroviruses. 10(7). 803–811. 14 indexed citations

18.

Okada, Takeshi, et al.. (1993). Aurothiolates Inhibit HIV-1 Infectivity by Gold(I) Ligand Exchange with a Component of the Virion Surface. Virology. 192(2). 631–642. 63 indexed citations

19.

Lichtor, Terry, George J. Dohrmann, & Mark E. Gurney. (1990). Cytokine Gene Expression by Human Gliomas. Neurosurgery. 26(5). 788–793. 26 indexed citations

20.

Roos, Raymond P., Sushil G. Devare, W G Robey, et al.. (1988). Restricted heterogeneity of antibody to gp120 and p24 in AIDS.. The Journal of Immunology. 141(1). 114–117. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact